Dyne Therapeutics, Inc. (DYN): Total Liabilities
$214.83M
As of 2025-12-31
$291.86M
As of 2026-06-30
+58.5%
3-year compound annual growth
+81.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $214.83M | +249.9% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $61.40M | -16.8% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $73.79M | +36.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $53.96M | -6.1% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $57.47M | +424.0% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $10.97M | +357.0% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $2.40M | n/a | 2021-03-04, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | 2025-12-31 | $214.83M | +249.9% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $1.30B | -21.3% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $456.88M | +32.5% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $656.90M | +128.2% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $86.39M | +33.0% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $401.41M | +18.0% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $104.11M | -14.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
Compare DYN, INDV, ZLAB, MDGL side by side · Screen every company in Pharmaceutical Preparations ↗